Venous Leg Ulcer Market

DelveInsight’s Venous Leg Ulcer Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LA, UNITED STATES, June 27, 2024 /EINPresswire.com/ --
DelveInsight’s “Venous Leg Ulcer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Venous Leg Ulcer, historical and forecasted epidemiology as well as the Venous Leg Ulcer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Venous Leg Ulcer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Venous Leg Ulcer Market Forecast

Some of the key facts of the Venous Leg Ulcer Market Report:
The Venous Leg Ulcer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In February 2024, MediWound reported favorable findings from a direct comparison of EscharEx and SANTYL in the ChronEx Phase II Randomized Controlled Study. The results showed that EscharEx, a gel containing bromelain, was superior to SANTYL, a collagenase ointment, in terms of wound debridement, promoting granulation tissue, and reducing the time to wound closure in patients with chronic venous leg ulcers (VLU).
According to Probst et al. (2023), venous ulcers are skin lesions that develop in areas affected by venous hypertension. In the United States, the prevalence of venous ulcers ranges from 1% to 3%. Additionally, 10% to 35% of adults in the US suffer from chronic venous insufficiency, and among adults aged 65 years and older, approximately 4% are affected by venous ulcers.
In the United States, women were observed to have a higher incidence of venous leg ulcers (VLU) than men in 2023, and these cases are anticipated to rise in the forecast period.
In the United States, the highest number of age-specific prevalent cases of venous leg ulcers (VLU) were recorded in 2023, with the highest incidence observed in older age groups, followed by other age categories.
Key Venous Leg Ulcer Companies: Xintela AB, Oneness Biotech Co., Ltd, Energenesis Biomedical Co., Ltd., Merakris Therapeutics, SolasCure, RHEACELL GmbH & Co. KG, Reponex Pharmaceuticals A/S, RegeneRx Biopharma, OcuNexus Therapeutics, Inc., Energenesis Biomedical, MediWound Ltd, Ilkos Therapeutic Inc., and others
Key Venous Leg Ulcer Therapies: XSTEM-VLU, ON101 Cream, ENERGI-F703 GEL, Dermacyte^®, Aurase Wound Gel, allo-APZ2-CVU, RNX-021, RNX-022, and RNX023, Thymosin Beta 4, Nexagon^®, rhGM-CSF + hydrogel, ENERGI-F703 GEL, EscharEx (5% EX-02 formulation), S42909, EscharEx (EX-02 formulation), and others
The Venous Leg Ulcer epidemiology based on gender analyzed that
The Venous Leg Ulcer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Venous Leg Ulcer pipeline products will significantly revolutionize the Venous Leg Ulcer market dynamics.

Venous Leg Ulcer Overview
Leg ulcers known as Venous Leg Ulcers are brought on by issues with blood circulation in the legs. Usually, the body's natural healing mechanism kicks into high gear as soon as a cut or scrape occurs. The wound eventually mends, but without adequate care, ulcers might not.

Get a Free sample for the Venous Leg Ulcer Market Report:
https://www.delveinsight.com/report-store/venous-leg-ulcer-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Venous Leg Ulcer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Venous Leg Ulcer Epidemiology Segmentation:
The Venous Leg Ulcer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Venous Leg Ulcer
Prevalent Cases of Venous Leg Ulcer by severity
Gender-specific Prevalence of Venous Leg Ulcer
Diagnosed Cases of Episodic and Chronic Venous Leg Ulcer

Download the report to understand which factors are driving Venous Leg Ulcer epidemiology trends @ Venous Leg Ulcer Epidemiology Forecast

Venous Leg Ulcer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Venous Leg Ulcer market or expected to get launched during the study period. The analysis covers Venous Leg Ulcer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Venous Leg Ulcer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Venous Leg Ulcer Therapies and Key Companies
Aurase Wound Gel: SolasCure
rhGM-CSF + hydrogel: Reponex Pharmaceuticals A/S
XSTEM-VLU: Xintela AB
ON101 Cream: Oneness Biotech Co., Ltd.
ENERGI-F703 GEL: Energenesis Biomedical Co., Ltd.
Dermacyte^®: Merakris Therapeutics

allo-APZ2-CVU: RHEACELL GmbH & Co. KG
RNX-021, RNX-022, and RNX023: Reponex Pharmaceuticals A/S
Thymosin Beta 4: RegeneRx Biopharma
Nexagon^®: OcuNexus Therapeutics, Inc.
rhGM-CSF + hydrogel: Reponex Pharma
ENERGI-F703 GEL: Energenesis Biomedical
EscharEx (5% EX-02 formulation): MediWound Ltd
S42909: Ilkos Therapeutic Inc.
EscharEx (EX-02 formulation): MediWound Ltd

Venous Leg Ulcer Market Drivers
Ongoing research is expanding our understanding of Venous Leg Ulcer pathophysiology, leading to improved treatment options.
Strong pipeline containing small molecule, gene and cell therapy, and the ongoing research in the development of novel products and therapies for the management of Venous Leg Ulcer is another key factor contributing to the growth of the Venous Leg Ulcer market

Venous Leg Ulcer Market Opportunities
Recent advances in ongoing clinical trials and developing pipelines of key players hold a huge potential to acquire a good market share.
In the recent years, there has been increased awareness across health care systems. Along with this, several pharmaceutical companies and government bodies are playing an important role in increasing awareness.

Scope of the Venous Leg Ulcer Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Venous Leg Ulcer Companies: Xintela AB, Oneness Biotech Co., Ltd, Energenesis Biomedical Co., Ltd., Merakris Therapeutics, SolasCure, RHEACELL GmbH & Co. KG, Reponex Pharmaceuticals A/S, RegeneRx Biopharma, OcuNexus Therapeutics, Inc., Energenesis Biomedical, MediWound Ltd, Ilkos Therapeutic Inc., and others
Key Venous Leg Ulcer Therapies: XSTEM-VLU, ON101 Cream, ENERGI-F703 GEL, Dermacyte^®, Aurase Wound Gel, allo-APZ2-CVU, RNX-021, RNX-022, and RNX023, Thymosin Beta 4, Nexagon^®, rhGM-CSF + hydrogel, ENERGI-F703 GEL, EscharEx (5% EX-02 formulation), S42909, EscharEx (EX-02 formulation), and others
Venous Leg Ulcer Therapeutic Assessment: Venous Leg Ulcer current marketed and Venous Leg Ulcer emerging therapies
Venous Leg Ulcer Market Dynamics: Venous Leg Ulcer market drivers and Venous Leg Ulcer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Venous Leg Ulcer Unmet Needs, KOL’s views, Analyst’s views, Venous Leg Ulcer Market Access and Reimbursement

To know more about Venous Leg Ulcer companies working in the treatment market, visit @ Venous Leg Ulcer Clinical Trials and Therapeutic Assessment

Table of Contents
1. Venous Leg Ulcer Market Report Introduction
2. Executive Summary for Venous Leg Ulcer
3. SWOT analysis of Venous Leg Ulcer
4. Venous Leg Ulcer Patient Share (%) Overview at a Glance
5. Venous Leg Ulcer Market Overview at a Glance
6. Venous Leg Ulcer Disease Background and Overview
7. Venous Leg Ulcer Epidemiology and Patient Population
8. Country-Specific Patient Population of Venous Leg Ulcer
9. Venous Leg Ulcer Current Treatment and Medical Practices
10. Venous Leg Ulcer Unmet Needs
11. Venous Leg Ulcer Emerging Therapies
12. Venous Leg Ulcer Market Outlook
13. Country-Wise Venous Leg Ulcer Market Analysis (2020–2034)
14. Venous Leg Ulcer Market Access and Reimbursement of Therapies
15. Venous Leg Ulcer Market Drivers
16. Venous Leg Ulcer Market Barriers
17. Venous Leg Ulcer Appendix
18. Venous Leg Ulcer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here